Table 3 Context to the nivolumab debate
From: Public participation: healthcare rationing in the newspaper media
Nivolumab as second-line treatment against non-small-cell lung cancer (NSCLC) of both squamous and non-squamous cell carcinoma was evaluated by New Methods in 2015. The initial incremental cost-effectiveness estimate of nivolumab compared to the standard of care for NSCLC patients was approximately US$175 K /QALY according to the Norwegian Medicines Agency, and 1150 patients were potentially eligible [46, 47]. The Decision Forum decided against implementing nivolumab twice in 2016 [48]. After tendering, the Decision Forum implemented a cheaper option, pembrolizumab (Keytruda), for the same indication in September 2016 [49]. |